Signal Advisors Wealth LLC Increases Stock Position in Eli Lilly and Company $LLY

Signal Advisors Wealth LLC boosted its position in shares of Eli Lilly and Company (NYSE:LLY) by 32.9% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 5,411 shares of the company’s stock after buying an additional 1,338 shares during the quarter. Signal Advisors Wealth LLC’s holdings in Eli Lilly and Company were worth $4,129,000 at the end of the most recent reporting period.

A number of other large investors have also modified their holdings of LLY. Wealth Preservation Advisors LLC purchased a new position in shares of Eli Lilly and Company in the 1st quarter valued at about $27,000. Sumitomo Mitsui Financial Group Inc. acquired a new stake in Eli Lilly and Company in the second quarter valued at approximately $27,000. Evolution Wealth Management Inc. acquired a new stake in Eli Lilly and Company in the second quarter valued at approximately $29,000. Steph & Co. increased its position in shares of Eli Lilly and Company by 290.0% in the third quarter. Steph & Co. now owns 39 shares of the company’s stock valued at $30,000 after buying an additional 29 shares in the last quarter. Finally, Financial Gravity Companies Inc. purchased a new stake in shares of Eli Lilly and Company in the second quarter valued at approximately $31,000. Institutional investors and hedge funds own 82.53% of the company’s stock.

Eli Lilly and Company News Roundup

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Late‑stage trial win — Lilly’s oral GLP‑1 pill orforglipron met the primary and all key secondary endpoints in the ATTAIN‑MAINTAIN Phase 3 trial, showing patients who switched from Wegovy or Zepbound kept essentially all prior weight loss; Lilly has submitted orforglipron to the FDA for obesity. PR Newswire: Lilly’s orforglipron helped people maintain weight loss
• Positive Sentiment: Program momentum and regulatory progress — Chugai and other releases highlight positive topline Phase 3 results and Lilly’s FDA filing for orforglipron, reinforcing the company’s leadership in oral GLP‑1s. This raises prospects for rapid commercial adoption if approved. TipRanks: Chugai highlights positive Phase 3 results
• Positive Sentiment: Analyst upgrades and upside forecasts — Bank of America and other outlets point to improved quality metrics and forecast material upside (BofA cites potential multi‑billion sales for new oral obesity therapies), while Daiwa upgraded LLY — all supportive of higher valuations. Benzinga: BofA sees room for stock upside American Banking News: Daiwa upgrade
• Neutral Sentiment: Pipeline depth — Lilly advanced eloralintide into Phase 3, strengthening its obesity/diabetes pipeline beyond orforglipron; this is strategic for longer‑term growth but not an immediate revenue driver. TipRanks: Lilly advances eloralintide into Phase 3
• Neutral Sentiment: Branding/marketing initiatives — Lilly’s consumer outreach (e.g., Olympics tie‑ins) supports awareness for new therapies but has unclear near‑term financial impact. MM&M: Lilly debuts video featuring Team USA
• Negative Sentiment: Pricing pressure in Canada — Reuters reported Lilly cut prices of Mounjaro and Zepbound in Canada by ~20% or more, which could compress margins or reduce realized revenue per prescription in markets facing tougher pricing/regulatory scrutiny. Reuters: Lilly cuts price of diabetes, weight-loss drugs in Canada

Wall Street Analyst Weigh In

LLY has been the topic of a number of research analyst reports. HSBC reissued a “hold” rating and issued a $1,070.00 price target on shares of Eli Lilly and Company in a research note on Wednesday, December 10th. BMO Capital Markets set a $1,200.00 target price on shares of Eli Lilly and Company in a research report on Thursday, December 4th. Guggenheim reissued a “buy” rating and set a $1,163.00 target price on shares of Eli Lilly and Company in a research note on Wednesday, December 3rd. Leerink Partnrs raised shares of Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a research note on Monday, November 10th. Finally, Hsbc Global Res upgraded Eli Lilly and Company from a “moderate sell” rating to a “hold” rating in a report on Wednesday, August 27th. Four research analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and five have assigned a Hold rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $1,155.36.

Eli Lilly and Company Price Performance

Shares of NYSE LLY opened at $1,071.35 on Monday. The firm has a 50-day simple moving average of $960.76 and a 200-day simple moving average of $831.36. The stock has a market capitalization of $1.01 trillion, a price-to-earnings ratio of 52.41, a price-to-earnings-growth ratio of 1.34 and a beta of 0.37. The company has a quick ratio of 1.24, a current ratio of 1.55 and a debt-to-equity ratio of 1.71. Eli Lilly and Company has a 52 week low of $623.78 and a 52 week high of $1,111.99.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings results on Thursday, October 30th. The company reported $7.02 earnings per share for the quarter, topping analysts’ consensus estimates of $6.42 by $0.60. Eli Lilly and Company had a net margin of 30.99% and a return on equity of 109.52%. The firm had revenue of $17.60 billion for the quarter, compared to analyst estimates of $16.09 billion. During the same period in the previous year, the business posted $1.18 earnings per share. Eli Lilly and Company’s quarterly revenue was up 53.9% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. On average, equities analysts predict that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, March 10th. Stockholders of record on Friday, February 13th will be given a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.6%. This is a boost from Eli Lilly and Company’s previous quarterly dividend of $1.50. The ex-dividend date is Friday, February 13th. Eli Lilly and Company’s dividend payout ratio (DPR) is currently 29.35%.

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.